The role of monoclonal antibodies in the management of leukemia

Ali Al-Ameri, Mohamad Cherry, Aref Al-Kali, Alessandra Ferrajoli

Research output: Contribution to journalReview articlepeer-review


This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33. The introduction of rituximab, an anti CD20 monoclonal antibody, had a great impact in the treatment of lymphoproliferative disorders. Gemtuzumab, an anti CD 33 conjugated monoclonal antibody has activity in acute mylegenous leukemia (AML). As this field is undergoing a rapid growth, the years will see an increasing use of monoclonal antibodies in hematological malignancies.

Original languageEnglish (US)
Pages (from-to)3258-3274
Number of pages17
Issue number10
StatePublished - Oct 18 2010


  • ALL
  • AML
  • CLL
  • Leukemia
  • Monoclonal Abs

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science


Dive into the research topics of 'The role of monoclonal antibodies in the management of leukemia'. Together they form a unique fingerprint.

Cite this